Phase 1 N=18 Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer
Head and Neck Neoplasm
Primary: Incidence of Dose-Limiting Toxicities at 50 Gy With Concurrent Atezolizumab — 2; 0; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=54 A Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VIS954 in Healthy Adult Participants
Healthy Volunteers
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) — 2; 1; 1; 1 Participants
Phase 1 N=7 Pharmacodynamic Evaluation of Intranasal Nalmefene
Pharmacodynamic
Primary: Change in Minute Ventilation — 3.432; 5.744 L/min — p=<0.0009
Phase 1 N=64 Trial to Determine MTD of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours and Later a Weekly Dosing Schedule in Selected Tumour Types
Neoplasms
Primary: Maximum Tolerated Dose (MTD) or Relevant Biological Dose (RBD) of BI 836845 During the First Treatment Course of the Dose Escalation Phase — 1000 mg
Phase 1 N=12 Study of LY3039478 in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Time Zero to the Last Time Point With a Measurable Concentration (AUC[0-tlast]) of…
Phase 1 N=14 Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)
Heart Failure With Reduced Ejection Fraction
Primary: Incidence and Severity of Treatment-emergent Adverse Events [Safety and Tolerability] — 4; 3; 8; 2 number of events
Phase 1 N=7 HUMC 1612: Optune NovoTTF-200A System
High Grade Glioma · Ependymoma
Primary: Safety of the Optune NovoTTF-200A System When Used Alone in Pediatric Patients With Recurrent High-grade Gliomas. — 0 Participants
Phase 1 N=20 A Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding a Native-like HIV Env Trimer and Interleukin-12 (INO-6160), Alone or in a Prime-boost Regimen With 3M-052-AF + Alum Adjuvanted VRC HIV Env Trimer 4571 in Adult Participants Without HIV
HIV-1-infection
Primary: Number of Participants Reporting Local Solicited Adverse Events Signs and Symptoms: Pain and/or Tenderness — 4; 0; 6; 7 Participants
Phase 1 N=24 Safety and Immunogenicity Study of Na-GST-1 With or Without CpG
Hookworm Infection · Hookworm Disease
Primary: Vaccine-related Adverse Events — 1; 3; 0; 3 Participants
Phase 1 N=13 Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mg
Opioid Overdose
Primary: Change in Minute Ventilation 5 Minutes From Opioid Induced Nadir — 4.42; 2.03 L/min
Phase 1 N=19 Non-invasive Vagal Nerve Stimulation in Alcohol Use Disorder
Alcohol Use Disorder
Primary: Treatment Acceptability Questionnaire (TAQ) — 5.7; 6.4 score on a scale
Phase 1 N=64 Lipopolysaccharide (LPS) Challenge in Depression
Major Depressive Disorder
Primary: Change in Snaith-Hamilton Pleasure Scale (SHAPS) — 38.4; 33.2; 27.2; 26.2 units on a scale
Phase 1 N=56 TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
Solid Tumor · Lymphoma
Primary: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Phase 1 N=16 Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer
Ovarian Cancer
Primary: Progression-free Survival. — 0; 0; 1 Participants
Phase 1 N=10 Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer
Anatomic Stage I Breast Cancer AJCC v8 · Anatomic Stage IA Breast Cancer AJCC v8 · Anatomic Stage IB Breast Cancer AJCC v8
Primary: Number of Adverse Events (Phase Ib) — 10; 2; 2; 1 Number of Events